Особенности метаболических показателей и маркеров системного воспаления у пациентов с расстройствами сна
Метаболический синдром
Дата публикации: декабря 20, 2014
Ключевые слова
расстройства сна
метаболические показатели
иммунологические показатели
метаболические показатели
иммунологические показатели
Как цитировать
Каллистов Д., Романов А., Гаврилова Е., Колганова Э. Особенности метаболических показателей и маркеров системного воспаления у пациентов с расстройствами сна // Кремлевская медицина. Клинический вестник. 2014. Т. № 1. С. 80-82.
Аннотация
Для уточнения механизмов негативного влияниярасстройств сна на состояние сердечно-сосудистой си-стемы проведено изучение особенностей углеводного илипидного обмена, маркеров системного воспаления иинтерлейкинового звена иммунитета в подгруппах па-циентов с нарушениями дыхания во время сна, больныхс хронической бессонницей и контрольной группе (все-го 253 пациента).Установлено, что у пациентов с синдромом обструк-тивного апноэ сна выявлялись повышенные значенияобщего холестерина, триглицеридов, коэффициентаатерогенности, С-реактивного белка и провоспалитель-ных интерлейкинов ИЛ – 1β и ИЛ - 6. Корреляцион-ный анализ показал наличие положительной корреля-ционной связи между уровнем С-реактивного белка ииндексом апноэ-гипопноэ (r=0,38), отрицательной кор-реляционной связи между минимальным уровнем Sa02и уровнем ИЛ-1β (r=0,35).Ключевые слова: расстройства сна, метаболическиепоказатели, иммунологические показатели.Metabolic parameters and systemic inflammation-relatedmarkers in patients with sleep disordersD.U. Kallistov, A.I. Romanov, E.S. Gavrilova, E.V. KolganovaRehabilitation Center, Department of Affairs Managementof President of Russian Federation, MoscowSummaryAmong 253 patients with sleep disorders the lipid and carbohydratemetabolism, systemic inflammation -related markersand interleukin immunity were evaluated in subgroups ofpatients with sleep apnoe syndrome, chronic sleep disordersand the control group. Patients with sleep apnoe syndromedemonstrated the increased level of total cholesterol, triglycerides,atherogenic factor, C-reactive protein, interleukin IL –1β and IL - 6. Positive correlation was demonstrated betweenlevel C-reactive protein and Apnoe-Hypnoe Index (r=0,38),negative correlation was demonstrated between minimal Sa02level and IL-1β level (r=0,35).Key words: sleep disorders, metabolic syndrome, immunologicalstatus.Литература
1. Coughlin S, Mawdsley L, Mugarza JA et al.
Obstructive sleep apnoea is independently associated with an
increased prevalence of metabolic syndrome. Eur Heart J.
2004;25:735–741.
2. Ford ES. Prevalence of the metabolic syndrome
defined by the International Diabetes Federation among adults
in the US. Diabetes Care. 2005; 28: 2745–2749.
3. Harsch IA, Pour Schahin S, Radespiel-Troger M
et al. CPAP treatment rapidly improves insulin sensitivity in
patients with OSAS. Am. J. Respir. Crit. Care Med. 2003;:.
4. Kahn R, Buse J, Ferrannini E, Stern M; American
Diabetes Association; European Association for the Study of
Diabetes. The metabolic syndrome: time for a critical appraisal:
joint statement from the American Diabetes Association and
the European Association for the Study of Diabetes. Diabetes
Care. 2005; 28: 2289–2304
5. Milleron O, Pilliere R, Foucher A et al. Benefits
of obstructive sleep apnoea treatment in coronary artery
disease: a long-term follow-up study. Eur Heart J.
2004;25:728–734.
6. Najarian RM, Sullivan LM, Kannel WB, Wilson
PW, D’Agostino RB, Wolf PA. Metabolic syndrome compared
with type 2 diabetes mellitus as a risk factor for stroke. Arch
Intern Med 2006;166:106-111
7. Narkiewicz K, Kato M, Phillips BG et al. Nocturnal
continuous positive airway pressure decreases daytime
sympathetic traffic in obstructive sleep apnea. Circulation.
1999;100:2332–2335.
8. Reaven G. Metabolic syndrome: Pathophysiology
and implications for management of cardiovascular disease.
Circulation. 2002;106:286–288.
9. Shamsuzzaman AS, Gersh BJ, Somers VK.
Obstructive sleep apnea: implications for cardiac and vascular
disease. JAMA. 2003;290:1906–1914.
10. Spiegel C, Knutson K, Leproult R, Tarsali E, Van
Cayter E. Sleep loss: a novel risk factor for insulin resistance
and type 2 diabetes. J Appl Physiol. 2005;99:2008–2009
11. Tasali E, Ip MSM. Obstructive Sleep Apnea and
Metabolic Syndrome. Alterations in Glucose Metabolism and
Inflammation. The Proceedings of the American Thoracic
Society 5:207-217 (2008)
12. Verdecchia Р, Angeli F, Borgioni C. Ambulatory Blood
Pressure and Cardiovascular Outcome in Relation to Perceived
Sleep Deprivation. Hypertension, Apr 2007; 49: 777 - 783
13. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso
M, Kuusisto J. The metabolic syndrome predicts incident
stroke. A14-year old study in elderly people in Finland. Stroke
2008;39:1078
14. Wilcox I, McNamara SG, Collins FL et al. «Syndrome
Z»: the interaction of sleep apnoea, vascular risk factors and
heart disease. Thorax. 1998;53(Suppl 3):S25–S28.
Obstructive sleep apnoea is independently associated with an
increased prevalence of metabolic syndrome. Eur Heart J.
2004;25:735–741.
2. Ford ES. Prevalence of the metabolic syndrome
defined by the International Diabetes Federation among adults
in the US. Diabetes Care. 2005; 28: 2745–2749.
3. Harsch IA, Pour Schahin S, Radespiel-Troger M
et al. CPAP treatment rapidly improves insulin sensitivity in
patients with OSAS. Am. J. Respir. Crit. Care Med. 2003;:.
4. Kahn R, Buse J, Ferrannini E, Stern M; American
Diabetes Association; European Association for the Study of
Diabetes. The metabolic syndrome: time for a critical appraisal:
joint statement from the American Diabetes Association and
the European Association for the Study of Diabetes. Diabetes
Care. 2005; 28: 2289–2304
5. Milleron O, Pilliere R, Foucher A et al. Benefits
of obstructive sleep apnoea treatment in coronary artery
disease: a long-term follow-up study. Eur Heart J.
2004;25:728–734.
6. Najarian RM, Sullivan LM, Kannel WB, Wilson
PW, D’Agostino RB, Wolf PA. Metabolic syndrome compared
with type 2 diabetes mellitus as a risk factor for stroke. Arch
Intern Med 2006;166:106-111
7. Narkiewicz K, Kato M, Phillips BG et al. Nocturnal
continuous positive airway pressure decreases daytime
sympathetic traffic in obstructive sleep apnea. Circulation.
1999;100:2332–2335.
8. Reaven G. Metabolic syndrome: Pathophysiology
and implications for management of cardiovascular disease.
Circulation. 2002;106:286–288.
9. Shamsuzzaman AS, Gersh BJ, Somers VK.
Obstructive sleep apnea: implications for cardiac and vascular
disease. JAMA. 2003;290:1906–1914.
10. Spiegel C, Knutson K, Leproult R, Tarsali E, Van
Cayter E. Sleep loss: a novel risk factor for insulin resistance
and type 2 diabetes. J Appl Physiol. 2005;99:2008–2009
11. Tasali E, Ip MSM. Obstructive Sleep Apnea and
Metabolic Syndrome. Alterations in Glucose Metabolism and
Inflammation. The Proceedings of the American Thoracic
Society 5:207-217 (2008)
12. Verdecchia Р, Angeli F, Borgioni C. Ambulatory Blood
Pressure and Cardiovascular Outcome in Relation to Perceived
Sleep Deprivation. Hypertension, Apr 2007; 49: 777 - 783
13. Wang J, Ruotsalainen S, Moilanen L, Lepisto P, Laakso
M, Kuusisto J. The metabolic syndrome predicts incident
stroke. A14-year old study in elderly people in Finland. Stroke
2008;39:1078
14. Wilcox I, McNamara SG, Collins FL et al. «Syndrome
Z»: the interaction of sleep apnoea, vascular risk factors and
heart disease. Thorax. 1998;53(Suppl 3):S25–S28.